论文部分内容阅读
目的分析生长抑素联合早期血液灌流治疗重症急性胰腺炎(SAP)的临床效果。方法 90例重症急性胰腺炎患者,按照随机双盲法分为A、B、C三组,各30例。三组患者入院均给予常规治疗,在此基础上,A组应用生长抑素治疗,B组应用早期血液灌流治疗,C组应用生长抑素联合早期血液灌流治疗。对比三组治疗效果。结果治疗后,C组患者白介素-10(IL-10)水平高于A、B组,白介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)水平低于A、B组,差异均具有统计学意义(P<0.05)。C组住院时间短于A、B组,差异具有统计学意义(P<0.05)。C组患者死亡率为3.33%,低于A、B组的23.33%、20.00%,差异均具有统计学意义(P<0.05)。结论生长抑素联合早期血液灌流治疗重症急性胰腺炎疗效确切,有利于改善炎性反应,降低死亡率,值得临床推广应用。
Objective To analyze the clinical effect of somatostatin combined with early hemoperfusion on severe acute pancreatitis (SAP). Methods Ninety patients with severe acute pancreatitis were divided into three groups according to a randomized double-blind method: A, B and C, 30 cases each. All three groups were given routine treatment. On the basis of this, group A received somatostatin treatment, group B received early hemoperfusion and group C received somatostatin combined with early hemoperfusion. Comparison of three groups of treatment. Results After treatment, the levels of interleukin-10 (IL-10) in group C were significantly higher than those in groups A and B, the levels of interleukin-18 and tumor necrosis factor-α were lower than those in groups A and B, The differences were statistically significant (P <0.05). The length of hospital stay in group C was shorter than that in group A and group B, with significant difference (P <0.05). The mortality rate in group C was 3.33%, which was lower than that in group A and B (23.33% and 20.00%, respectively). The difference was statistically significant (P <0.05). Conclusion Somatostatin combined with early hemoperfusion for severe acute pancreatitis has definite curative effect, which is beneficial to improve inflammatory response and reduce mortality, which is worthy of clinical application.